X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8733) 8733
Publication (628) 628
Newsletter (228) 228
Book Review (119) 119
Magazine Article (56) 56
Newspaper Article (41) 41
Dissertation (38) 38
Book Chapter (27) 27
Conference Proceeding (16) 16
Trade Publication Article (8) 8
Web Resource (4) 4
Data Set (2) 2
Transcript (2) 2
Paper (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
alendronate (6167) 6167
humans (5360) 5360
female (4370) 4370
osteoporosis (4313) 4313
index medicus (3329) 3329
aged (2487) 2487
middle aged (2452) 2452
male (2214) 2214
endocrinology & metabolism (2135) 2135
bisphosphonates (2127) 2127
alendronate - therapeutic use (1779) 1779
bone density conservation agents - therapeutic use (1711) 1711
animals (1637) 1637
postmenopausal women (1636) 1636
bone density - drug effects (1556) 1556
osteoporosis - drug therapy (1466) 1466
fractures (1463) 1463
osteoporosis, postmenopausal - drug therapy (1385) 1385
orthopedics (1368) 1368
women (1365) 1365
bone density (1203) 1203
diphosphonates - therapeutic use (1169) 1169
bone-mineral density (1120) 1120
postmenopausal osteoporosis (1107) 1107
aged, 80 and over (1086) 1086
risk (1073) 1073
risk factors (1044) 1044
bones (949) 949
bone density conservation agents - administration & dosage (927) 927
bone density conservation agents - adverse effects (925) 925
bisphosphonate (915) 915
alendronate - administration & dosage (910) 910
drug therapy (908) 908
rats (899) 899
therapy (896) 896
risedronate (869) 869
rheumatology (855) 855
treatment outcome (852) 852
medicine & public health (851) 851
alendronate - pharmacology (845) 845
medicine, general & internal (841) 841
adult (833) 833
prevention (830) 830
density (806) 806
alendronate - adverse effects (776) 776
bone mineral density (756) 756
vertebral fractures (756) 756
zoledronic acid (746) 746
bone (739) 739
diphosphonates - administration & dosage (712) 712
diphosphonates - adverse effects (698) 698
pharmacology & pharmacy (690) 690
health aspects (687) 687
research (681) 681
care and treatment (663) 663
bone density conservation agents - pharmacology (632) 632
analysis (615) 615
endocrinology (583) 583
mineral density (571) 571
diphosphonates - pharmacology (555) 555
time factors (550) 550
fractures, bone - prevention & control (529) 529
in-vitro (508) 508
hip fracture (498) 498
diphosphonates (497) 497
etidronic acid - analogs & derivatives (497) 497
bone remodeling - drug effects (491) 491
fracture (491) 491
surgery (491) 491
randomized-trial (477) 477
administration, oral (466) 466
mice (454) 454
double-blind method (451) 451
drug administration schedule (451) 451
risedronate sodium (445) 445
absorptiometry, photon (438) 438
bone and bones - drug effects (432) 432
dentistry, oral surgery & medicine (425) 425
phosphonates (420) 420
dosage and administration (419) 419
denosumab (409) 409
turnover (408) 408
teriparatide (405) 405
retrospective studies (404) 404
pamidronate (393) 393
resorption (389) 389
abridged index medicus (386) 386
dose-response relationship, drug (386) 386
double-blind (386) 386
etidronic acid - therapeutic use (382) 382
parathyroid-hormone (378) 378
medicine, research & experimental (377) 377
radiography (376) 376
osteoporosis - complications (373) 373
follow-up studies (372) 372
trial (368) 368
biochemical markers (364) 364
hormone replacement therapy (364) 364
dentistry (362) 362
osteoporosis - prevention & control (350) 350
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8372) 8372
German (156) 156
Spanish (108) 108
Japanese (92) 92
French (68) 68
Portuguese (59) 59
Korean (51) 51
Chinese (47) 47
Turkish (30) 30
Italian (24) 24
Russian (22) 22
Norwegian (19) 19
Polish (17) 17
Danish (10) 10
Czech (6) 6
Slovak (6) 6
Croatian (5) 5
Dutch (5) 5
Hungarian (4) 4
Swedish (4) 4
Finnish (2) 2
Persian (2) 2
Serbian (2) 2
Slovenian (2) 2
Ukrainian (2) 2
Bulgarian (1) 1
Hebrew (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of Allergy and Clinical Immunology, ISSN 0091-6749, 08/2019, Volume 144, Issue 2, p. 416
for the AsthmaNet Investigators Loss of bronchoprotection (LOBP) with a regularly used long-acting [beta].sub.2-adrenergic receptor agonist (LABA) is well... 
Alendronate
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2004, Volume 350, Issue 12, pp. 1189 - 1199
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 15, pp. 1417 - 1427
Among postmenopausal women with osteoporosis and a high risk of fracture, treatment with the monoclonal antibody romosozumab for 12 months followed by... 
MEDICINE, GENERAL & INTERNAL | METAANALYSIS | BONE-MINERAL DENSITY | VERTEBRAL FRACTURES | DISEASE | AORTA | RANDOMIZED-TRIAL | RISK | STRENGTH | POSTMENOPAUSAL WOMEN | SCLEROSTEOSIS | Humans | Antibodies, Monoclonal - adverse effects | Fractures, Bone - epidemiology | Antibodies, Monoclonal - therapeutic use | Risk | Bone Remodeling - drug effects | Alendronate - therapeutic use | Incidence | Spinal Fractures - prevention & control | Female | Drug Therapy, Combination | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Antibodies, Monoclonal - pharmacology | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Osteoporosis, Postmenopausal - drug therapy | Bone Density Conservation Agents - pharmacology | Alendronate - adverse effects | Bone Density - drug effects | Alendronate - pharmacology | Least-Squares Analysis | Aged | Cardiovascular Diseases - chemically induced | Fractures, Bone - prevention & control | Treatment outcome | Care and treatment | Fractures | Growth | Analysis | Monoclonal antibodies | Bones | Research | Jaw | Femur | Vertebrae | Immunoglobulins | Inhibitor drugs | Osteonecrosis | SOST protein | Bisphosphonates | Hip | Post-menopause | Bone resorption | Osteoporosis | Alendronic acid | Bone growth | Bone density | Drug therapy | Osteogenesis | randomized-trial | metaanalysis | disease | postmenopausal women | strength | bone-mineral density | Klinisk medicin | vertebral fractures | sclerosteosis | Clinical Medicine | aorta | risk | General & Internal Medicine
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2007, Volume 357, Issue 20, pp. 2028 - 2039
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 01/2010, Volume 25, Issue 1, pp. 72 - 81
Journal Article
02/2013
Background: Osteoporosis is a chronic disease characterized by a decrease in bone mineral density (BMD) and corruption of the microarchitectural structure of... 
Methylprednisolon | Osteoporosis | Ovariectomy | Alendronate | Metyrosine
Web Resource
Biomaterials, ISSN 0142-9612, 2013, Volume 34, Issue 15, pp. 3795 - 3806
Abstract Paclitaxel (PTX) and alendronate (ALN) are effective drugs used for the treatment of breast cancer bone metastases. Growing evidence suggests that... 
Advanced Basic Science | Dentistry | Angiogenesis | Dendrimers | PEG | Bone targeting | Alendronate | Polymer therapeutics | MATERIALS SCIENCE, BIOMATERIALS | ENGINEERING, BIOMEDICAL | PACLITAXEL | MACROMOLECULAR THERAPEUTICS | BISPHOSPHONATES | ANTICANCER | HIGH-RISK | PROSTATE-CANCER | AGENTS | DRUG-DELIVERY SYSTEMS | Neovascularization, Physiologic - drug effects | Paclitaxel - pharmacology | Human Umbilical Vein Endothelial Cells - metabolism | Apoptosis - drug effects | Humans | Bone Neoplasms - secondary | Polyethylene Glycols - chemistry | Antineoplastic Agents - therapeutic use | Paclitaxel - pharmacokinetics | Tibia - pathology | Alendronate - chemistry | Alendronate - therapeutic use | Paclitaxel - chemistry | Human Umbilical Vein Endothelial Cells - cytology | Micelles | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Bone Neoplasms - drug therapy | Alendronate - pharmacokinetics | Tissue Distribution - drug effects | Human Umbilical Vein Endothelial Cells - drug effects | Treatment Outcome | Antineoplastic Agents - chemistry | Tibia - drug effects | Breast Neoplasms - drug therapy | Paclitaxel - therapeutic use | Xenograft Model Antitumor Assays | Animals | Fluorescein-5-isothiocyanate | Breast Neoplasms - pathology | Alendronate - pharmacology | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Ethylene glycol | Care and treatment | Phosphonates | Paclitaxel | Aluminum compounds | Fluorescence | Breast cancer | Metastasis | Drug therapy | Cancer | Index Medicus | Drugs | Imaging | Breast | Bones | Conjugation | Tumors
Journal Article
Journal of Bone and Mineral Research, ISSN 0884-0431, 08/2010, Volume 25, Issue 8, pp. 1886 - 1894
Journal Article
Clinical calcium, ISSN 0917-5857, 2009, Volume 19, Issue 7, pp. 970 - 975
Journal Article
Osteoporosis International, ISSN 0937-941X, 1/2012, Volume 23, Issue 1, pp. 317 - 326
The final analysis of this 2-year, randomized, crossover study showed that postmenopausal women with osteoporosis were more adherent, compliant, and persistent... 
Adherence | Persistence | Medicine & Public Health | Alendronate | Compliance | Orthopedics | Gynecology | Rheumatology | Denosumab | Endocrinology | MEDICATION | FRACTURE RATES | OSTEOPOROSIS | LOW BONE MASS | THERAPY | INJECTION | PATIENT PREFERENCE | ENDOCRINOLOGY & METABOLISM | BELIEFS | QUESTIONNAIRE | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Alendronate - therapeutic use | Antibodies, Monoclonal, Humanized | Injections, Subcutaneous | Female | Bone Density Conservation Agents - adverse effects | Drug Administration Schedule | Administration, Oral | Bone Density Conservation Agents - therapeutic use | Treatment Outcome | Patient Preference | Bone Density Conservation Agents - administration & dosage | Osteoporosis, Postmenopausal - drug therapy | Cross-Over Studies | Alendronate - adverse effects | Bone Density - drug effects | Medication Adherence | RANK Ligand - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Osteoporosis, Postmenopausal - physiopathology | Aged | Alendronate - administration & dosage | Patient compliance | Research | Clinical trials | Comparative studies | Drug therapy | Womens health | Alendronic acid | Osteoporosis | Bone mineral density | Tablets | Bisphosphonates | Post-menopause | Original
Journal Article